Search results for " network meta-analysis"

showing 2 items of 2 documents

Effect of pharmacological interventions and placebo on liver Histology in nonalcoholic steatohepatitis: A network meta-analysis

2022

Background: The aims of this study were to quantify the histological improvement and its risk factors in patients with NASH enrolled in the placebo arms of randomized controlled trials (RCTs), and to indirectly compare the effect of several investigational drugs for NASH on validated histological outcomes.Data synthesis: A comprehensive search was conducted to detect phase 2 and 3 RCTs comparing pharmacological interventions in patients with NASH. According to Food and Drug Administra-tion (FDA) recommendations, primary outcomes included: 1) NASH resolution without wors-ening of fibrosis; 2) At least 1-point reduction in fibrosis without worsening of NASH. Meta -analysis and meta-regression…

Liver CirrhosisNutrition and DieteticsLiverNon-alcoholic Fatty Liver DiseaseEndocrinology Diabetes and MetabolismNetwork Meta-AnalysisMeta-analysis NASH Network meta-analysisMedicine (miscellaneous)HumansVitamin EDrugs InvestigationalCardiology and Cardiovascular MedicineRandomized Controlled Trials as Topic
researchProduct

Network meta-analysis of randomized trials in multiple myeloma: Efficacy and safety in frontline therapy for patients not eligible for transplant

2022

The treatment scenario for newly-diagnosed transplant-ineligible multiple myeloma patients (NEMM) is quickly evolving. Currently, combinations of proteasome inhibitors (PI) and/or immunomodulatory drugs (IMiD) +/- the monoclonal antibody Daratumumab are used for first-line treatment, even if head-to-head comparisons are lacking. To compare efficacy and safety of these regimens, we performed a network meta-analysis (NMA) of 27 phase 2/3 randomized trials including a total of 12935 patients and 23 different schedules. Four efficacy/outcome and one safety indicators were extracted and integrated to obtain (for each treatment) the surface under the cumulative ranking-curve (SUCRA), a metric use…

multiple myelomaCancer ResearchOncologyprincipal component analysisnon-transplant eligibleI line treatment multiple myeloma network meta-analysis non-transplant eligible principal component analysisHematologyGeneral MedicineSettore MED/15 - Malattie del SangueI line treatmentnetwork meta-analysisI line treatment; multiple myeloma; network meta-analysis; non-transplant eligible; principal component analysis;
researchProduct